



# Total pancreatectomy for recurrent acute and chronic pancreatitis: a critical review of patient selection criteria

Mahya Faghih<sup>b</sup>, Francisco Garcia Gonzalez<sup>b</sup>, Martin A. Makary<sup>c</sup>,  
and Vikesh K. Singh<sup>a,b</sup>

## Purpose of review

Critical review of the indications for total pancreatectomy and highlight limitations in current diagnostic criteria for chronic pancreatitis.

## Recent findings

The diagnosis of noncalcific chronic pancreatitis remains controversial because of an overreliance on nonspecific imaging and laboratories findings. Endoscopic ultrasound, s-magnetic resonance cholangiopancreatography, and/or endoscopic pancreatic function testing are often used to diagnose noncalcific chronic pancreatitis despite the fact that there is no gold standard for this condition. Abdominal pain is not specific for chronic pancreatitis and is more likely to be encountered in patients with functional gastrointestinal disorders based on the high incidence of these conditions. The duration of pain and opioid analgesic use results in central sensitization that adversely affects pain outcomes after total pancreatectomy. An alcoholic cause is associated with poorer pain outcomes after total pancreatectomy.

## Summary

The lack of a gold standard for noncalcific chronic pancreatitis limits the diagnostic accuracy of imaging and laboratory tests. The pain of chronic pancreatitis is nonspecific and is affected by duration, preoperative opioid use, and cause. These factors will need to be considered in the development of future selection criteria for this morbid surgery.

## Keywords

acute recurrent pancreatitis, chronic abdominal pain, chronic pancreatitis, total pancreatectomy

## INTRODUCTION

Chronic pancreatitis is a progressive, inflammatory disorder characterized by irreversible morphological changes and a gradual loss of exocrine and endocrine function [1–3]. In contrast, recurrent acute pancreatitis (RAP) can present without symptoms in between episodes but ongoing episodes over time eventually lead to morphologic changes and functional deficits of chronic pancreatitis. Both disorders are believed to be part of a disease continuum. The difficulty encountered by most practitioners is that the diagnosis of chronic pancreatitis is based on advanced morphologic changes (e.g. calcifications) and functional deficits but there are no accurate tests for early stages of the disease. Chronic abdominal pain (CAP) is the most common and morbid symptom of chronic pancreatitis but is not specific for chronic pancreatitis.

Total pancreatectomy can reduce pain, improve quality of life (QOL), and eliminate the risk of

developing pancreatic cancer in chronic pancreatitis [1]. Because of the potential morbidity and mortality associated with total pancreatectomy, patient selection is crucial to achieve optimal outcomes. The present article will review current selection criteria for total pancreatectomy and discuss recent data that should be incorporated into future criteria. Islet autotransplantation is also often pursued in eligible patients at the time of total pancreatectomy but is beyond the scope of this review.

<sup>a</sup>Pancreatitis Center, <sup>b</sup>Division of Gastroenterology and <sup>c</sup>Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

Correspondence to Vikesh K. Singh, MD, MSc, Division of Gastroenterology, Johns Hopkins Hospital, 1830 E. Monument Street, Room 428, Baltimore, MD 21205, USA. Tel: +1 410 614 6708; fax: +1 410 614 7631; e-mail: vsingh1@jhmi.edu

**Curr Opin Gastroenterol** 2017, 33:330–338

DOI:10.1097/MOG.0000000000000390

## KEY POINTS

- There is no 'gold standard' for the diagnosis of noncalcific chronic pancreatitis.
- Chronic 'pancreatic-type' pain is nonspecific for chronic pancreatitis as many functional gastrointestinal disorders can present with similar pain.
- Patients with chronic pancreatitis with alcohol and smoking causes are less likely to benefit from total pancreatectomy than patients with HGP.
- Total pancreatectomy should also be avoided in patients with pancreas divisum and chronic abdominal pain who do not have unequivocal evidence of RAP or chronic pancreatitis.
- Duration of pain more than 2–3 years and opioid use are associated with poor pain outcome after intervention for chronic pancreatitis.
- Use of gabapentin prior to surgery may result in less opioid use in the postoperative period.

## SELECTION CRITERIA FOR TOTAL PANCREATECTOMY

Of the dozen or so centers that perform total pancreatectomy in the United States, there are only two centers that have published their selection criteria [4,5]. The primary limitation of these criteria include an overemphasis on imaging and functional assessments for diagnosing noncalcific chronic pancreatitis (NCCP), in particular, the use of endoscopic ultrasound, secretin-enhanced magnetic resonance cholangiopancreatography (MRCP), and endoscopic pancreatic function testing. The second limitation surrounds the oversimplification of abdominal pain associated with chronic pancreatitis. What many label as 'pancreatic-type abdominal pain' is not visceral pancreatic pain because of central sensitization that occurs over time and is greatly impacted by opioid use.

## EPIDEMIOLOGY OF CHRONIC PANCREATITIS

The incidence of chronic pancreatitis is estimated to be between 2 and 200/100 000 individuals per year worldwide [6–10]. This variability in incidence likely reflects the limitations of the diagnostic criteria currently used for chronic pancreatitis. Furthermore, many patients with the diagnosis of chronic pancreatitis have other causes for their CAP. Patients with functional dyspepsia and irritable bowel syndrome (IBS) experience symptoms that overlap with other chronic gastroduodenal disorders and are often misdiagnosed as chronic pancreatitis [11].

The pooled prevalence of undiagnosed dyspepsia was reported to be 21% [95% confidence interval (CI), 18–24] across 100 population-based studies [12]. The leading gastrointestinal reason for an emergency visit in 2012 was a functional or motility disorder, diagnosed in 11.2% of all gastrointestinal patients [13]. A recent long-term study (1980–2012) of emergency room visits in Finland showed non-specific abdominal pain was the most common diagnosis [14]. A recent survey study of 1924 patients with a history of gastrointestinal symptoms showed 43% were not formally diagnosed with IBS despite meeting the diagnostic criteria for this condition [15].

## DIAGNOSIS OF CHRONIC PANCREATITIS

Recent guidelines by American Pancreatic Association [1] and United European Gastroenterology [16] focus primarily on radiologic and endoscopic studies for diagnosing chronic pancreatitis. A summary of the limitations of current diagnostic studies are presented in Table 1.

There is no gold standard for the diagnosis of chronic pancreatitis. Although prior studies utilized histologic fibrosis as the gold standard for chronic pancreatitis, fibrosis can also be seen in advanced age [28–31], alcohol use [32,33], diabetes mellitus [34], smoking [35], chronic kidney disease [36], and obesity [1] in the absence of any clinical or radiographic features of chronic pancreatitis. Furthermore, pancreatic morphology has not been shown to correlate with the severity of pain, even with advanced changes of chronic pancreatitis (e.g. calcifications) [37,38,39]. Current endoscopic and surgical interventions are largely directed towards patients with a dilated pancreatic duct on the presumption that increased intraductal pressure leads to abdominal pain. However, there is poor correlation between the treatment of pancreatic obstruction caused by stones and/or strictures and pain relief [40,41,42].

## ENDOSCOPIC AND IMAGING STUDIES

The Cambridge classification is used diagnoses and grade the severity of chronic pancreatitis based on pancreatic ductal changes seen during endoscopic retrograde cholangiopancreatography (ERCP) [43,44]. However, this classification has low sensitivity and specificity for the diagnosis of chronic pancreatitis. In addition, the interpretation of pancreatography is operator dependent and cannot assess parenchymal changes. Computed tomography (CT) and MRCP play an important role in the early detection of pancreatic calcifications and dilation of

**Table 1.** Advantages and disadvantages of standard tests commonly used to diagnose chronic pancreatitis

Standard Test	Advantages	Limitations
Imaging Tests [3,17,18 <sup>a</sup> ,19,20]		
CT	Highly sensitive for the detection of calcification and assessment of pancreatic duct dilation	Imaging does not diagnose noncalcific chronic pancreatitis
MRCP	Evaluate bile and pancreatic ducts T1-weighted images can show chronic inflammation and fibrosis in early stages of CP	Low sensitivity in noncalcific CP Difficult to assess subtle changes in main pancreatic duct and side branches
EUS	More reliable for parenchymal and ductal assessment More sensitive than CT	Operator dependent Changes could be result of aging, smoking, alcohol use and obesity
Functional Tests [21–27]		
Stimulating tests (Secretin, CCK Stimulation Tests)	PPV (45%) and NPV (97%) suggests ability of test to exclude CP in those with CAP	Invasive  Costly Sedation, fluid contamination, CFTR mutation and smoking affect pancreatic fluid volume and bicarbonate concentrations
FE-1	Simple, rapid  Inexpensive  Can be performed in outpatient setting	Not as sensitive as stimulation tests using secretagogues  Requires patient compliance with procurement and handling of specimen
MTG-BT	Noninvasive	Test takes 6 h to perform Not commercially available in all countries

CAP, chronic abdominal pain; CCK, cholecystokinin; CT, computed tomography; EPI, exocrine pancreatic insufficiency; FE-1, fecal elastase-1; MRCP, magnetic resonance cholangiopancreatography; MTG-BT, mixed-triglyceride breath test; NPV, negative predictive value; PPV, positive predictive value.

the pancreatic duct [3]. Although the diagnosis of calcific chronic pancreatitis on abdominal imaging is relatively straightforward, there is no gold standard for the diagnosis of NCCP (Table 1). EUS provides high-resolution imaging of the entire gland, providing a detailed parenchymal and ductal assessment, and is considered to be more sensitive than CT [45]. Multiple studies have attempted to correlate EUS findings with histopathology in chronic pancreatitis patients (Table 1) [46,47]. However, these studies have been limited by small sample size, the fact biopsies may not be representative of changes present in nonsampled areas of the pancreas [48–50], many patients underwent resection for pancreatic cancer (Table 1) and patients who were included had variable pretest probabilities for chronic pancreatitis (Table 1).

## ASSESSMENT OF PANCREATIC EXOCRINE FUNCTION

Pancreatic exocrine insufficiency (PEI) occurs when there is insufficient production and/or secretion of pancreatic digestive enzymes. Although chronic pancreatitis is the most frequent cause of PEI, there

are other pancreatic diseases in which PEI occurs because of the loss of pancreas parenchyma including pancreatic necrosis, pancreatic cancer, partial surgical resection of the pancreas, cystic fibrosis, and obstruction of the pancreatic duct [51–53]. However, the pancreas has a large functional reserve, and malabsorption leading to steatorrhea is not expected until lipase output is reduced to less than 10% of normal [54]. Multiple tests are available for the detection of PEI, including fecal elastase-1 (FE-1), C<sup>13</sup> mixed-triglyceride breath test (MTG-BT), and the pancreatic function test (PFT) [55].

FE-1 is a simple indirect test for the evaluation of PEI (Table 1) [56]. However, it only has sensitivity between 54 and 75% (Table 1) [56–58]. Furthermore, there is no consensus regarding the threshold for diagnosing PEI using FE-1, and values ranging from 15 to 200 µg/g have been suggested in the literature (Table 1) [31,55,59]. A recent prospective study comparing FE-1, MTG-BT, and a 72-h fecal fat test found that a cut-off value of 84 µg/g was associated with a sensitivity and specificity of 87.5 and 66.7% for PEI, respectively (Table 1). Several studies have shown that direct PFT has the highest sensitivity for detecting PEI (Table 1) [59,60]. A retrospective

study of secretin-stimulated endoscopic PFT found a sensitivity of 86% and a specificity of 67% for histologic fibrosis (Table 1). However, there are also limitations to ePFT. The procedure is cumbersome, as pancreatic juice needs to be collected 1 h after secretin administration for assessment of the peak bicarbonate concentration [61]. Sedation [62,63], fluid contamination (Table 1), CFTR mutations (Table 1), and smoking [64,65] can affect the pancreatic fluid volume and bicarbonate concentrations. Moreover, there is no reference range for a normal bicarbonate concentration across a large population of patients [66].

## CAUSE AND RISK FACTORS

### Alcohol and smoking

Chronic alcohol consumption is implicated as the primary etiologic factor in 44–53% of patients with chronic pancreatitis in the United States [7,67]. A recent meta-analysis found a strong correlation between drinking more than 40 g/day and the development of pancreatitis [68]. However, only 3% of heavy drinkers develop chronic pancreatitis [69]. There is a problem of overdiagnosis of chronic pancreatitis in individuals who drink moderately and have abdominal pain because the threshold of drinking that increases chronic pancreatitis risk is not widely known. Recent studies have shown that men are more likely to have alcoholic pancreatitis than women (58.2 vs. 30.3%; OR = 3.2; 95% CI, 2.2–4.7) [70]. This is could be because of higher prevalence of heavy alcohol consumption among male patients with alcoholic pancreatitis as a previous study by Lowenfels *et al.* [71] showed that, at equal levels of alcohol consumption, the rates of alcoholic pancreatitis are similar for males and females. Several studies evaluating endoscopic and surgical interventions for alcoholic chronic pancreatitis have showed better pain outcomes in nonalcoholic patients with chronic pancreatitis [72–75]. Another study of alcoholic patients ( $n=30$ ) found reduced QOL and no improvement in pain after TPIAT compared to patients with nonalcoholic chronic pancreatitis ( $n=70$ ) [76].

Smoking is a strong and independent risk factor for chronic pancreatitis [67,77–80] and the combination of alcohol and smoking leads to the highest cumulative risk for developing chronic pancreatitis [42,81,82]. Furthermore, prior studies of smokers with chronic pancreatitis have shown that they also have poor pain outcomes after surgical and endoscopic intervention [83,84]. Smoking is associated with the progression from acute pancreatitis to chronic pancreatitis [82], development and

progression of calcifications [8,85–87], and an increased risk of pancreatic cancer. Previous studies have shown that the risk for pancreatic cancer decreases a decade after smoking cessation, when compared to current smokers [88].

### Pancreas divisum

Pancreas divisum is the most common congenital anomaly in humans, present in 5–10% of the global population [89,90]. Retrospective studies have shown that pancreas divisum does not modify the natural history of disease among alcoholic and non-alcoholic patients with chronic pancreatitis [91,92]. Furthermore, recent studies suggest that gene mutations such as CFTR and SPINK-1 are the underlying cause for pancreatitis in individuals with pancreas divisum [93,94]. A recent study of patients with chronic pancreatitis who underwent TP-IAT showed that pancreas divisum was independently associated with persistent abdominal pain in the first year after surgery (OR = 2.5; 95% CI, 1.1–5.6) [95]. It is not clear whether total pancreatectomy was pursued in these patients because they had clear evidence of RAP or chronic pancreatitis versus CAP.

### Recurrent acute pancreatitis

RAP is defined as at least 2 episodes of acute pancreatitis [4,96,97]. The diagnostic value of serum lipase and amylase in acute pancreatitis is unclear. Approximately 10% of patients may be incorrectly diagnosed with acute pancreatitis because of non-specific elevations in pancreatic enzymes [98]. A recent Cochrane review assessed the diagnostic accuracy of index pancreatic enzyme levels in patients who presented to the emergency department with abdominal pain. This study found that a significant number of patients diagnosed with acute pancreatitis had enzymes less than three times the upper limit of normal. This could be partially related to delayed presentation for medical evaluation because of short half-life of serum amylase and lipase [99]. Among 100 patients with lipase and amylase levels less than three times the upper limit of normal, only 68 and 74 patients had acute pancreatitis, respectively [98]. There are many other causes of elevated lipase that could be misdiagnosed as acute pancreatitis [100]. Therefore, the diagnosis of RAP should not be based solely on the presence of abdominal pain and pancreatic enzyme elevations. Abdominal imaging within 72 h of symptom onset showing acute pancreatitis on at least two occasions should be required to make diagnosis of RAP. Because abdominal imaging is commonly pursued in patients with acute pancreatitis, this requirement

for a diagnosis of RAP is important for their subsequent management particularly because the majority of patients with chronic pancreatitis have a preceding history of RAP [82].

### HEREDITARY/GENETIC PANCREATITIS

Hereditary/genetic pancreatitis (HGP) is the likely etiology for a large number of patients with idiopathic pancreatitis. Prior studies reported gene mutation prevalence in 12–43% of idiopathic chronic pancreatitis and 30–60% in idiopathic RAP [101–107]. One of the limitations of these studies was the evaluation of subsets of the mutations associated with pancreatitis. As additional mutations become available for commercial testing, it is quite likely that a greater proportion of patients will have a pathogenic variant found on testing.

The first symptoms of HGP, usually acute pancreatitis, often begin during childhood. Progression of disease with morphologic changes begins at a median age of 22–25 years [108,109]. The risk of developing pancreatic cancer among patients with PRSS1 mutations is as high as 53.5% (95% CI, 7–76%) by the age of 75 [110], which is 50–70 times greater than the general population [111,112]. This risk will be higher among chronic smokers [108,109]. Patients with HGP who are smokers have a cumulative risk of pancreatic cancer that is more than 50% at age 70, which is two-fold higher than patients with HGP who do not smoke. In addition, pancreatic cancer develops 20 years earlier than general population [71,112,113]. The risk of pancreatic cancer associated with other genetic mutations is not as well established as with PRSS1 mutations [108,111]. There is recent data on pancreatic cancer in chronic pancreatitis because of SPINK1 mutations [114,115<sup>□</sup>]. Since the progression of chronic pancreatitis, as measured by the development of calcifications, is more rapid in patients with SPINK1 versus PRSS1 mutations, [116] the risk of pancreatic cancer may be greater as well, because it has been shown that number of calcification(s) is significantly associated with fibrosis in chronic pancreatitis [40<sup>□</sup>].

Patients with HGP are excellent candidates for total pancreatectomy as they can benefit from pain relief, and prevention of acute recurrent pancreatitis and pancreatic cancer. A 10-year follow-up study by Chinnakotla *et al.* [108] demonstrated a significant improvement in pain, better metabolic outcomes and less opioid analgesic use in the HGP group ( $n=80$ ) when compared to the non-HGP group ( $n=404$ ). It should also be noted that partial pancreatectomy and/or drainage procedures resulted in subsequent completion pancreatectomy among 42 (66%) patients with idiopathic chronic pancreatitis

in one series [116]. Therefore, total pancreatectomy may be the preferred approach in idiopathic chronic pancreatitis to avoid redo surgery.

### DURATION OF THE DISEASE

The timing for an elective surgery such as total pancreatectomy is controversial. Prior studies showed that advanced chronic pancreatitis increases the risk of central sensitization [117<sup>□</sup>,118], poor pain relief [119<sup>□</sup>], malignancy, and mortality in chronic pancreatitis [82,120–122]. A recent meta analysis of 406 patient from three studies showed that surgery performed early in the course of chronic pancreatitis was associated with higher rates of complete pain relief after surgery (RR=1.67; 95% CI, 1.09–2.56;  $P=0.02$ ) [123]. Another retrospective study of 66 patients with a median chronic pancreatitis duration of 28 months (interquartile range, 12–67) showed that the optimal time for surgery was within 26.5 months from diagnosis and was associated with less pain and opioid dependence over 3 years of follow-up [119<sup>□</sup>]. Three or more endoscopically inserted stents has also been shown to be an independent risk factor for persistent abdominal pain 1 year following total pancreatectomy [95]. This is likely because of the collinearity between the number of stents inserted and the duration of disease. Overall, the data from these studies suggest that surgical intervention should be considered earlier during the disease course.

### CENTRAL SENSITIZATION IN CHRONIC PANCREATITIS

CAP is experienced by almost 90% [123] of patients with chronic pancreatitis and half of them report having constant pain, which has a significant impact on QOL [124,125<sup>□</sup>,126]. Neuropathic changes best correlate with pain in chronic pancreatitis [127]. Nociceptive afferents selectively respond to nerve damage and local inflammation and the sensitization of these afferents can result in changes in central pain processing, which is a common in patients with chronic pancreatitis [128–130]. Over time, ongoing nociceptive afferent barrage of the central nervous system results in loss of the descending inhibitory control and activation of the descending facilitator mechanism [131]. This can lead patients with chronic pancreatitis to experience pain in the absence of painful stimuli (allodynia) or experience increased pain with only mildly painful stimuli (hyperalgesia), even after total pancreatectomy. A recent study compared pain outcomes in patients with chronic pancreatitis after surgical decompression or resection and showed that poorer outcomes were associated with

**Table 2.** Johns Hopkins criteria for total pancreatectomy**Indications for total pancreatectomy**

## I. Documented CP

- (i) Chronic abdominal pain with one of the following:
- (ii) Calcification (s)
- (iii) Moderate to severe ductal changes on Cambridge criteria
- (iv) Histology confirmed CP on prior surgery
- (v) RAP

## II. RAP with impaired QOL

Two or more episodes of acute pancreatitis with confirmed imaging and no evidence of a treatable etiology

## III. Documented hereditary/genetic pancreatitis with either I and/or II

Contraindications for total pancreatectomy

## I. Alcoholic/smoking etiology

## II. Active substance addiction/abuse

## III. Duration of pain &gt;3 years

## IV. Opioid use longer &gt;3 years unless patient can successfully wean off and initiate centrally acting drugs (e.g. gabapentinoids) prior to surgery

## V. Poorly controlled psychiatric comorbidity

## VI. Medical noncompliance

CP, chronic pancreatitis; HGP, hereditary genetic pancreatitis; QOL, quality of life; RAP, recurrent acute pancreatitis.

increased central sensitization based on neurosensory testing [132].

**OPIOID ANALGESICS**

Chronic opioid use can result in effective analgesia in some patients with chronic pancreatitis but long-term use associated with considerable adverse effects, such as abuse, dependence, overdose, and opioid induced hyperalgesia, which can be difficult to diagnose and treat [133]. Furthermore, several studies have shown that preoperative opioid use increases the risk of failing to achieving complete long-term pain relief after an endoscopic or surgical intervention [134–137]. A recent prospective study by Negi *et al.* suggested that surgery should be performed before initiating opioids for pain relief. Their results were confirmed in a long-term follow up study of 266 patients, which found that a duration of pain more than 3 years (OR = 1.81; 95% CI, 1.02–3.37) and preoperative daily opioid use (OR = 2.14; 95% CI, 1.23–3.96) were independently associated with persistent severe pain after pancreatic surgery [134]. Opioids are not effective in chronic pancreatitis patients with central sensitization [138]; rather, pharmacologic treatments for chronic pancreatitis should directly target the central nervous system. A recent meta-analysis evaluating 1793

patients across 17 randomized control trials showed that the use of gabapentin prior to surgery resulted in less opioid use and dependence in the postoperative period [139\*].

The duration of opioid use should be considered when determining the optimal timing of surgery [4]. Therapeutic education and behavioral support before and after surgery are essential components in the management of chronic pancreatitis.

**CONCLUSION**

We summarize our criteria for total pancreatectomy in Table 2. Our criteria incorporate many aspects of the data presented in this review.

**Acknowledgements**

None.

**Financial support and sponsorship**

None.

**Conflicts of interest**

V.K.S.: Consultant to Novo Nordisk, Akcea, Ariel Precision Medicine, and Abbvie. Advisory board participant for Nordmark. These financial interests do not pertain directly to this work. All the other authors have no disclosures.

**REFERENCES AND RECOMMENDED READING**

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Conwell DL, Lee LS, Yadav D, *et al.* American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. *Pancreas* 2014; 43:1143–1162.
2. Forsmark CE. Management of chronic pancreatitis. *Gastroenterology* 2013; 144:1282–1291; e3.
3. Ketwaroo GA, Freedman SD, Sheth SG. Approach to patients with suspected chronic pancreatitis: a comprehensive review. *Pancreas* 2015; 44:173–180.
4. Sutherland DE, Radosevich DM, Bellin MD, *et al.* Total pancreatectomy and islet autotransplantation for chronic pancreatitis. *J Am Coll Surg* 2012; 214:409–424; discussion 424–6.
5. Morgan KA, Borckardt J, Balliet W, *et al.* How are select chronic pancreatitis patients selected for total pancreatectomy with islet autotransplantation? Are there psychometric predictors? *J Am Coll Surg* 2015; 220:693–698.
6. Ni Q, Yun L, Roy M, Shang D. Advances in surgical treatment of chronic pancreatitis. *World J Surg Oncol* 2015; 13; 34-014-0430-4.
7. Yadav D, Timmons L, Benson JT, *et al.* Incidence, prevalence, and survival of chronic pancreatitis: a population-based study. *Am J Gastroenterol* 2011; 106:2192–2199.
8. Hirota M, Shimosegawa T, Masamune A, *et al.* The seventh nationwide epidemiological survey for chronic pancreatitis in Japan: clinical significance of smoking habit in Japanese patients. *Pancreatol* 2014; 14:490–496.
9. Tillou JD, Tatum JA, Jolissaint JS, *et al.* Operative management of chronic pancreatitis: a review. *Am J Surg* 2017. [Epub ahead of print]
10. Levy P, Dominguez-Munoz E, Imrie C, *et al.* Epidemiology of chronic pancreatitis: burden of the disease and consequences. *United European Gastroenterol J* 2014; 2:345–354.
11. Talley NJ. Functional dyspepsia: advances in diagnosis and therapy. *Gut Liver* 2017; 11:349–357.

12. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. *Gut* 2015; 64:1049–1057.
13. Peery AF, Crockett SD, Barritt AS, *et al.* Burden of gastrointestinal, liver, and pancreatic diseases in the United States. *Gastroenterology* 2015; 149:1731–1741.e3.
14. Fagerstrom A, Paajanen P, Saarelainen H, *et al.* Nonspecific abdominal pain remains as the most common reason for acute abdomen: 26-year retrospective audit in one emergency unit. *Scand J Gastroenterol* 2017; 1–6.
15. Sayuk GS, Wolf R, Chang L. Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol* 2017; 112:892–899.
16. Lohr JM, Dominguez-Munoz E, Rosendahl J, *et al.* United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). *United European Gastroenterol J* 2017; 5:153–199.
17. Ammann RW. The natural history of alcoholic chronic pancreatitis. *Intern Med* 2001; 40:368–375.
18. Trikudanathan G, Vega-Peralta J, Malli A, *et al.* Diagnostic performance of endoscopic ultrasound (EUS) for non-calcific chronic pancreatitis (NCCP) based on histopathology. *Am J Gastroenterol* 2016; 111:568–574.
- This recent study showed there is a poor correlation between standard EUS features and histopathology in NCCP.
19. Albashir S, Bronner MP, Parsi MA, *et al.* Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis. *Am J Gastroenterol* 2010; 105:2498–2503.
20. Varadarajulu S, Eltoum I, Tamhane A, Eloubeidi MA. Histopathologic correlates of noncalcific chronic pancreatitis by EUS: a prospective tissue characterization study. *Gastrointest Endosc* 2007; 66:501–509.
21. Manfredi R, Costamagna G, Brizi MG, *et al.* Severe chronic pancreatitis versus suspected pancreatic disease: dynamic MR cholangiopancreatography after secretin stimulation. *Radiology* 2000; 214:849–855.
22. Pezzilli R, Morselli-Labate AM, Frulloni L, *et al.* The quality of life in patients with chronic pancreatitis evaluated using the SF-12 questionnaire: a comparative study with the SF-36 questionnaire. *Dig Liver Dis* 2006; 38:109–115.
23. Manfredi R, Lucidi V, Gui B, *et al.* Idiopathic chronic pancreatitis in children: MR cholangiopancreatography after secretin administration. *Radiology* 2002; 224:675–682.
24. Hellerhoff KJ, Helmberger H 3rd, Rosch T, *et al.* Dynamic MR pancreatography after secretin administration: image quality and diagnostic accuracy. *AJR Am J Roentgenol* 2002; 179:121–129.
25. Dominguez-Munoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P. Fecal elastase test: evaluation of a new noninvasive pancreatic function test. *Am J Gastroenterol* 1995; 90:1834–1837.
26. Gonzalez-Sanchez V, Amrani R, Gonzalez V, Trigo C, *et al.* Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-mixed triglyceride breath test versus fecal elastase. *Pancreatol* 2017. [Epub ahead of print]
27. Hart PA, Topazian M, Raimondo M, *et al.* Endoscopic pancreas fluid collection: methods and relevance for clinical care and translational science. *Am J Gastroenterol* 2016; 111:1258–1266.
28. Bhutani MS, Arantes VN, Verma D, *et al.* Histopathologic correlation of endoscopic ultrasound findings of chronic pancreatitis in human autopsies. *Pancreas* 2009; 38:820–824.
29. Detlefsen S, Sipsos B, Feyereabend B, Kloppel G. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. *Virchows Arch* 2005; 447:800–805.
30. Hastier P, Buckley MJ, Dumas R, *et al.* A study of the effect of age on pancreatic duct morphology. *Gastrointest Endosc* 1998; 48:53–57.
31. Anand BS, Vij JC, Mac HS, *et al.* Effect of aging on the pancreatic ducts: a study based on endoscopic retrograde pancreatography. *Gastrointest Endosc* 1989; 35:210–213.
32. Pitchumoni CS, Glasser M, Saran RM, *et al.* Pancreatic fibrosis in chronic alcoholics and nonalcoholics without clinical pancreatitis. *Am J Gastroenterol* 1984; 79:382–388.
33. Hastier P, Buckley MJ, Francois E, *et al.* A prospective study of pancreatic disease in patients with alcoholic cirrhosis: comparative diagnostic value of ERCP and EUS and long-term significance of isolated parenchymal abnormalities. *Gastrointest Endosc* 1999; 49:705–709.
34. Mohapatra S, Majumder S, Smyrk TC, *et al.* Diabetes mellitus is associated with an exocrine pancreatopathy: conclusions from a review of literature. *Pancreas* 2016; 45:1104–1110.
- This recent review found that pancreatic fibrosis and exocrine insufficiency in diabetes frequently occur in the absence of clinical or histopathological evidence of chronic pancreatitis.
35. van Geenen EJ, Smits MM, Schreuder TC, *et al.* Smoking is related to pancreatic fibrosis in humans. *Am J Gastroenterol* 2011; 106:1161–1166; quiz 1167.
36. Avram MM. High prevalence of pancreatic disease in chronic renal failure. *Nephron* 1977; 18:68–71.
37. Chowdhury R, Bhutani MS, Mishra G, *et al.* Comparative analysis of direct pancreatic function testing versus morphological assessment by endoscopic ultrasonography for the evaluation of chronic unexplained abdominal pain of presumed pancreatic origin. *Pancreas* 2005; 31:63–68.
38. Wilcox CM, Yadav D, Ye T, *et al.* Chronic pancreatitis pain pattern and severity are independent of abdominal imaging findings. *Clin Gastroenterol Hepatol* 2015; 13:552–560; quiz e28-9.
- This is a prospective multicenter study of patients chronic pancreatitis from 2008 to 2012 at 13 tertiary centers in the United States evaluating the patterns and severity of pain.
39. Frokjaer JB, Olesen SS, Drewes AM. Fibrosis atrophy, and ductal pathology in chronic pancreatitis are associated with pancreatic function but independent of symptoms. *Pancreas* 2013; 42:1182–1187.
40. Sinha A, Patel YA, Cruise M, *et al.* Predictors of post-operative pain relief in patients with chronic pancreatitis undergoing the frey or whipple procedure. *J Gastrointest Surg* 2016; 20:734–740.
- This recent study showed that number of calcification(s) is significantly associated with fibrosis in chronic pancreatitis.
41. Frey CF, Amikura K. Local resection of the head of the pancreas combined with longitudinal pancreaticojejunostomy in the management of patients with chronic pancreatitis. *Ann Surg* 1994; 220:492–504; discussion 504-7.
42. Lankisch PG, Lohr-Happe A, Otto J, Creutzfeldt W. The natural course of chronic pancreatitis—pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. *Zentralbl Chir* 1995; 120:278–286.
43. Axon AT, Classen M, Cotton PB, *et al.* Pancreatography in chronic pancreatitis: international definitions. *Gut* 1984; 25:1107–1112.
44. Riff BP, Chandrasekhara V. The role of endoscopic retrograde cholangiopancreatography in management of pancreatic diseases. *Gastroenterol Clin North Am* 2016; 45:45–65.
45. Iglesias-Garcia J, Dominguez-Munoz JE. Endoscopic ultrasound image enhancement elastography. *Gastrointest Endosc Clin N Am* 2012; 22:333–348; x-xi.
46. Chong AK, Hawes RH, Hoffman BJ, *et al.* Diagnostic performance of EUS for chronic pancreatitis: a comparison with histopathology. *Gastrointest Endosc* 2007; 65:808–814.
47. LeBlanc JK, Chen JH, Al-Haddad M, *et al.* Endoscopic ultrasound and histology in chronic pancreatitis: how are they associated? *Pancreas* 2014; 43:440–444.
48. Will U, Mueller A, Topalidis T, Meyer F. Value of endoscopic ultrasonography-guided fine needle aspiration (FNA) in the diagnosis of neoplastic tumor-(like) pancreatic lesions in daily clinical practice. *Ultraschall Med* 2010; 31:169–174.
49. Fritscher-Ravens A, Brand L, Knofel WT, Bobrowski C, *et al.* Comparison of endoscopic ultrasound-guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma and chronic pancreatitis. *Am J Gastroenterol* 2002; 97:2768–2775.
50. Krishna NB, Mehra M, Reddy AV, Agarwal B. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. *Gastrointest Endosc* 2009; 70:70–79.
51. Vujasinovic M, Valente R, Del Chiaro M, *et al.* Pancreatic exocrine insufficiency in pancreatic cancer. *Nutrients* 2017; 9. doi: 10.3390/nu9030183.
52. Gibson-Corley KN, Meyerholz DK, Engelhardt JF. Pancreatic pathophysiology in cystic fibrosis. *J Pathol* 2016; 238:311–320.
53. Boreham B, Ammori BJ. A prospective evaluation of pancreatic exocrine function in patients with acute pancreatitis: correlation with extent of necrosis and pancreatic endocrine insufficiency. *Pancreatol* 2003; 3:303–308.
54. Benini L, Amodio A, Campagnola P, *et al.* Fecal elastase-1 is useful in the detection of steatorrhea in patients with pancreatic diseases but not after pancreatic resection. *Pancreatol* 2013; 13:38–42.
55. Lohr JM, Oliver MR, Frulloni L. Synopsis of recent guidelines on pancreatic exocrine insufficiency. *United European Gastroenterol J* 2013; 1:79–83.
56. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. *Gut* 1996; 39:580–586.
57. Siegmund E, Lohr JM, Schuff-Werner P. The diagnostic validity of noninvasive pancreatic function tests—a meta-analysis. *Z Gastroenterol* 2004; 42:1117–1128.
58. Naruse S, Ishiguro H, Ko SB, *et al.* Fecal pancreatic elastase: a reproducible marker for severe exocrine pancreatic insufficiency. *J Gastroenterol* 2006; 41:901–908.
59. Pezzilli R, Andriulli A, Bassi C, *et al.* Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. *World J Gastroenterol* 2013; 19:7930–7946.
60. Thody AJ, Smith AG. Hormones and skin pigmentation in the mammal. *Int J Dermatol* 1977; 16:657–664.
61. Draganov P, George S, Toskes PP, Forsmark CE. Is a 15-min collection of duodenal secretions after secretin stimulation sufficient to diagnose chronic pancreatitis? *Pancreas* 2004; 28:89–92.
62. Conwell DL, Zuccaro G, Purich E, *et al.* The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT). *Am J Gastroenterol* 2005; 100:1161–1166.

63. Konturek SJ. Opiates and the gastrointestinal tract. *Am J Gastroenterol* 1980; 74:285–291.
64. Barreto SG. How does cigarette smoking cause acute pancreatitis? *Pancreatol* 2016; 16:157–163.
65. Kadiyala V, Lee LS, Banks PA, *et al.* Cigarette smoking impairs pancreatic duct cell bicarbonate secretion. *JOP* 2013; 14:31–38.
66. Draganov P, Patel A, Fazel A, *et al.* Prospective evaluation of the accuracy of the intraductal secretin stimulation test in the diagnosis of chronic pancreatitis. *Clin Gastroenterol Hepatol* 2005; 3:695–699.
67. Cote GA, Yadav D, Sliwka A, *et al.* Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. *Clin Gastroenterol Hepatol* 2011; 9:266–273; quiz e27.
68. Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: a systematic review and a series of meta-analyses. *EBioMedicine* 2015; 2:1996–2002.
69. Yadav D, Eigenbrodt ML, Briggs MJ, *et al.* Pancreatitis: prevalence and risk factors among male veterans in a detoxification program. *Pancreas* 2007; 34:390–398.
70. Conwell DL, Banks PA, Sandhu BS, *et al.* Validation of demographics, etiology, and risk factors for chronic pancreatitis in the USA: a report of the North American Pancreas Study (NAPS) Group. *Dig Dis Sci* 2017. [Epub ahead of print]
- This recent validation study confirms the changing trends in chronic pancreatitis epidemiology.
71. Lowenfels AB, Maisonneuve P, DiMaggio EP, *et al.* Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. *J Natl Cancer Inst* 1997; 89:442–446.
72. Ammann RW, Largiader F, Akovbiantz A. Pain relief by surgery in chronic pancreatitis? Relationship between pain relief, pancreatic dysfunction, and alcohol withdrawal. *Scand J Gastroenterol* 1979; 14:209–215.
73. Bhat KR, Khajanchi M, Prajapati R, Satoskar RR. Evaluation of pain preoperatively and postoperatively in patients with chronic pancreatitis undergoing longitudinal pancreaticojejunostomy. *Indian J Surg* 2015; 77(Suppl 3):1098–1102.
74. Hayakawa T, Kondo T, Shibata T, *et al.* Chronic alcoholism and evolution of pain and prognosis in chronic pancreatitis. *Dig Dis Sci* 1989; 34:33–38.
75. Scuro LA, Vantini I, Piubello W, *et al.* Evolution of pain in chronic relapsing pancreatitis: a study of operated and nonoperated patients. *Am J Gastroenterol* 1983; 78:495–501.
76. Dunderdale J, McAuliffe JC, McNeal SF, *et al.* Should pancreatectomy with islet cell autotransplantation in patients with chronic alcoholic pancreatitis be abandoned? *J Am Coll Surg* 2013; 216:591–596; discussion 596–8.
77. Lin Y, Tamakoshi A, Hayakawa T, *et al.* Cigarette smoking as a risk factor for chronic pancreatitis: a case-control study in Japan. Research Committee on Intractable Pancreatic Diseases. *Pancreas* 2000; 21:109–114.
78. Law R, Parsi M, Lopez R, *et al.* Cigarette smoking is independently associated with chronic pancreatitis. *Pancreatol* 2010; 10:54–59.
79. Tolstrup JS, Kristiansen L, Becker U, Gronbaek M. Smoking and risk of acute and chronic pancreatitis among women and men: a population-based cohort study. *Arch Intern Med* 2009; 169:603–609.
80. Yadav D, Hawes RH, Brand RE, *et al.* Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. *Arch Intern Med* 2009; 169:1035–1045.
81. Ahmed Ali U, Issa Y, Hagenaaers JC, Bakker OJ, *et al.* Risk of recurrent pancreatitis and progression to chronic pancreatitis after a first episode of acute pancreatitis. *Clin Gastroenterol Hepatol* 2016; 14:738–746.
- This recent study evaluated a large number of patients with comprehensive follow-up and detailed data on their first episode of acute pancreatitis.
82. Sankaran SJ, Xiao AY, Wu LM, *et al.* Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. *Gastroenterology* 2015; 149:1490–1500; e1.
83. Delhaye M, Arvanitakis M, Verset G, *et al.* Long-term clinical outcome after endoscopic pancreatic ductal drainage for patients with painful chronic pancreatitis. *Clin Gastroenterol Hepatol* 2004; 2:1096–1106.
84. Seven G, Schreiner MA, Ross AS, Lin OS, *et al.* Long-term outcomes associated with pancreatic extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. *Gastrointest Endosc* 2012; 75:997–1004; e1.
85. Imoto M, DiMaggio EP. Cigarette smoking increases the risk of pancreatic calcification in late-onset but not early-onset idiopathic chronic pancreatitis. *Pancreas* 2000; 21:115–119.
86. Maisonneuve P, Lowenfels AB, Mullhaupt B, *et al.* Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. *Gut* 2005; 54:510–514.
87. Luaces-Regueira M, Iglesias-Garcia J, Lindkvist B, *et al.* Smoking as a risk factor for complications in chronic pancreatitis. *Pancreas* 2014; 43:275–280.
88. Michaud DS. Epidemiology of pancreatic cancer. *Minerva Chir* 2004; 59:99–111.
89. Stram M, Liu S, Singhi AD. Chronic pancreatitis. *Surg Pathol Clin* 2016; 9:643–659.
90. Skorzewska M, Romanowicz T, Mielko J, *et al.* Frey operation for chronic pancreatitis associated with pancreas divisum: case report and review of the literature. *Prz Gastroenterol* 2014; 9:175–178.
91. Barthet M, Valantin V, Spinosa S, *et al.* Clinical course and morphological features of chronic calcifying pancreatitis associated with pancreas divisum. *Eur J Gastroenterol Hepatol* 1995; 7:993–998.
92. Spicak J, Poulouva P, Plucnarova J, *et al.* Pancreas divisum does not modify the natural course of chronic pancreatitis. *J Gastroenterol* 2007; 42:135–139.
93. Bertin C, Pelletier AL, Vullierme MP, *et al.* Pancreas divisum is not a cause of pancreatitis by itself but acts as a partner of genetic mutations. *Am J Gastroenterol* 2012; 107:311–317.
94. DiMaggio MJ, DiMaggio EP. Pancreas divisum does not cause pancreatitis, but associates with CFTR mutations. *Am J Gastroenterol* 2012; 107:318–320.
95. Chinnakotla S, Beilman GJ, Dunn TB, *et al.* Factors predicting outcomes after a total pancreatectomy and islet autotransplantation lessons learned from over 500 cases. *Ann Surg* 2015; 262:610–622.
96. Bellin MD, Freeman ML, Gelrud A, *et al.* Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. *Pancreatol* 2014; 14:27–35.
97. Bellin MD, Kerdsirichairat T, Beilman GJ, *et al.* Total pancreatectomy with islet autotransplantation improves quality of life in patients with refractory recurrent acute pancreatitis. *Clin Gastroenterol Hepatol* 2016; 14:1317–1323.
98. Rompanesi G, Hann A, Komolafe O, *et al.* Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis. *Cochrane Database Syst Rev* 2017; 4:CD012010.
99. Sternby B, O'Brien JF, Zinsmeister AR, DiMaggio EP. What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study. *Mayo Clin Proc* 1996; 71:1138–1144.
100. Hameed AM, Lam VW, Pleass HC. Significant elevations of serum lipase not caused by pancreatitis: a systematic review. *HPB (Oxford)* 2015; 17:99–112.
101. Cavestro GM, Zuppardo RA, Bertolini S, *et al.* Connections between genetics and clinical data: Role of MCP-1, CFTR, and SPINK-1 in the setting of acute, acute recurrent, and chronic pancreatitis. *Am J Gastroenterol* 2010; 105:199–206.
102. Pelaez-Luna M, Robles-Diaz G, Canizales-Quinteros S, Tusie-Luna MT. PRSS1 and SPINK1 mutations in idiopathic chronic and recurrent acute pancreatitis. *World J Gastroenterol* 2014; 20:11788–11792.
103. Weiss FU, Simon P, Bogdanova N, *et al.* Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. *Gut* 2005; 54:1456–1460.
104. Masson E, Chen JM, Audrezet MP, *et al.* A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTFR and CFTR genes in 253 young French patients. *PLoS One* 2013; 8:e73522.
105. Truninger K, Witt H, Kock J, *et al.* Mutations of the serine protease inhibitor, Kazal type 1 gene, in patients with idiopathic chronic pancreatitis. *Am J Gastroenterol* 2002; 97:1133–1137.
106. Rosendahl J, Landt O, Bernadova J, *et al.* CFTR, SPINK1, CTFR and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? *Gut* 2013; 62:582–592.
107. Palermo JJ, Lin TK, Hornung L, *et al.* Genophenotypic analysis of pediatric patients with acute recurrent and chronic pancreatitis. *Pancreas* 2016; 45:1347–1352.
108. Chinnakotla S, Radosevich DM, Dunn TB, *et al.* Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. *J Am Coll Surg* 2014; 218:530–543.
109. Rebours V, Levy P, Ruzsniwski P. An overview of hereditary pancreatitis. *Dig Liver Dis* 2012; 44:8–15.
110. Rebours V, Boutron-Ruault MC, Schnee M, *et al.* The natural history of hereditary pancreatitis: a national series. *Gut* 2009; 58:97–103.
111. Whitcomb DC, Shelton CA, Brand RE. Genetics and genetic testing in pancreatic cancer. *Gastroenterology* 2015; 149:1252–1264; e4.
112. Lowenfels AB, Maisonneuve P, Whitcomb DC. Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. *Med Clin North Am* 2000; 84:565–573.
113. Lowenfels AB, Maisonneuve P, Whitcomb DC, *et al.* Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. *JAMA* 2001; 286:169–170.
114. Shimosegawa T, Kume K, Satoh K. Chronic pancreatitis and pancreatic cancer: prediction and mechanism. *Clin Gastroenterol Hepatol* 2009; 7(11 Suppl):S23–S28.
115. Midha S, Sreenivas V, Kabra M, *et al.* Genetically determined chronic pancreatitis but not alcoholic pancreatitis is a strong risk factor for Pancreatic Cancer. *Pancreas* 2016; 45:1478–1484.
- This is a recent study estimate the risk of pancreatic cancer in patients with CP.
116. Keim V, Witt H, Bauer N, *et al.* The course of genetically determined chronic pancreatitis. *JOP* 2003; 4:146–154.
117. Wilson GC, Sutton JM, Smith MT, *et al.* Completion pancreatectomy and islet cell autotransplantation as salvage therapy for patients failing previous operative interventions for chronic pancreatitis. *Surgery* 2015; 158:872–878; discussion 879–80.
- This is the first study to assess the quality of life after salvage therapy with completion pancreatectomy.

118. Bouwense SA, Olesen SS, Drewes AM, *et al.* Is altered central pain processing related to disease stage in chronic pancreatitis patients with pain? An exploratory study. *PLoS One* 2013; 8:e55460.
119. Yang CJ, Bliss LA, Freedman SD, *et al.* Surgery for chronic pancreatitis: the role of early surgery in pain management. *Pancreas* 2015; 44:819–823.
- This is the first study from the United States confirms that patients with chronic pancreatitis benefits from early surgery and this is the first study calculated optimal cutoff times for surgery.
120. Cahen DL, Gouma DJ, Laramée P, *et al.* Long-term outcomes of endoscopic vs surgical drainage of the pancreatic duct in patients with chronic pancreatitis. *Gastroenterology* 2011; 141:1690–1695.
121. Cahen DL, van Berkel AM, Oskam D, *et al.* Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis. *Eur J Gastroenterol Hepatol* 2005; 17:103–108.
122. Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. *Lancet* 2011; 377:1184–1197.
123. Yang CJ, Bliss LA, Schapira EF, *et al.* Systematic review of early surgery for chronic pancreatitis: impact on pain, pancreatic function, and re-intervention. *J Gastrointest Surg* 2014; 18:1863–1869.
124. Mullady DK, Yadav D, Amann ST, *et al.* Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort study. *Gut* 2011; 60:77–84.
125. Machicado JD, Amann ST, Anderson MA, *et al.* Quality of life in chronic pancreatitis is determined by constant pain, disability/unemployment, current smoking, and associated co-morbidities. *Am J Gastroenterol* 2017; 112:633–642.
- large multicenter cross-sectional study showed constant pain impairs the QOL of chronic pancreatitis.
126. Wehler M, Nichterlein R, Fischer B, *et al.* Factors associated with health-related quality of life in chronic pancreatitis. *Am J Gastroenterol* 2004; 99:138–146.
127. Ceyhan GO, Bergmann F, Kadihasanoglu M, *et al.* Pancreatic neuropathy and neuropathic pain—a comprehensive pathomorphological study of 546 cases. *Gastroenterology* 2009; 136:177–186; e1.
128. Buscher HC, van Goor H, Wilder-Smith OH. Effect of thoracoscopic splanchnic denervation on pain processing in chronic pancreatitis patients. *Eur J Pain* 2007; 11:437–443.
129. Dimcevski G, Sami SA, Funch-Jensen P, *et al.* Pain in chronic pancreatitis: the role of reorganization in the central nervous system. *Gastroenterology* 2007; 132:1546–1556.
130. Pasricha PJ. Unraveling the mystery of pain in chronic pancreatitis. *Nat Rev Gastroenterol Hepatol* 2012; 9:140–151.
131. Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. *Pain* 2009; 141:191–209.
132. Bouwense SA, Ahmed Ali U, ten Broek RP, *et al.* Altered central pain processing after pancreatic surgery for chronic pancreatitis. *Br J Surg* 2013; 100:1797–1804.
133. Wilder-Smith OH, Schreyer T, Scheffer GJ, Arendt-Nielsen L. Patients with chronic pain after abdominal surgery show less preoperative endogenous pain inhibition and more postoperative hyperalgesia: a pilot study. *J Pain Palliat Care Pharmacother* 2010; 24:119–128.
134. Ahmed Ali U, Nieuwenhuijs VB, van Eijck CH, *et al.* Clinical outcome in relation to timing of surgery in chronic pancreatitis: a nomogram to predict pain relief. *Arch Surg* 2012; 147:925–932.
135. Alexakis N, Connor S, Ghaneh P, Raraty M, *et al.* Influence of opioid use on surgical and long-term outcome after resection for chronic pancreatitis. *Surgery* 2004; 136:600–608.
136. Negi S, Singh A, Chaudhary A. Pain relief after Frey's procedure for chronic pancreatitis. *Br J Surg* 2010; 97:1087–1095.
137. Issa Y, van Santvoort HC, van Goor H, *et al.* Surgical and endoscopic treatment of pain in chronic pancreatitis: a multidisciplinary update. *Dig Surg* 2013; 30:35–50.
138. van Esch AA, Wilder-Smith OH, Jansen JB, *et al.* Pharmacological management of pain in chronic pancreatitis. *Dig Liver Dis* 2006; 38:518–526.
139. Arumugam S, Lau CS, Chamberlain RS. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. *J Pain Res* 2016; 9:631–640.
- Meta-analysis found that preoperative gabapentin reduces postoperative pain among patients undergoing elective surgery.